stockportfolio.pro
Stocks / NTRA vs RPRX
NTRA vs RPRX
Natera, Inc. and Royalty Pharma plc side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Natera, Inc. (NTRA) | Royalty Pharma plc (RPRX) | |
|---|---|---|
| Market cap | $31.0B | $31.6B |
| Revenue (latest FY) | $2.31B | $2.38B |
| Net income (latest FY) | $-208.16M | $770.95M |
| Revenue growth (5y CAGR) | 42.6% | 2.3% |
| Net margin | -9.0% | 32.4% |
| Return on equity | -12.2% | 11.9% |
| P/E ratio | — | 28.9 |
| Dividend yield | — | 1.7% |
| Profitable years (of last 10) | 0 | 8 |
| Positive free cash flow | Yes | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open NTRA — free Open RPRX — freeFrequently asked questions
Which is bigger, NTRA or RPRX?
Royalty Pharma plc is larger by market capitalization — $31.6B versus $31.0B.
Which grows faster, NTRA or RPRX?
Over the last five fiscal years, Natera, Inc. grew revenue faster — 42.6%/yr versus 2.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.